Evidence map›Paper›PMID 40713053›Full record

ArticleBMJ open2025

Development of a core outcome set for the trials of complementary therapies in people with multiple sclerosis: international survey and consensus meetings.

Jesus Lopez-Alcalde, Anna K Tietjen, Yuqian Yan, Claudia Canella, Jürgen Barth, Nina Steinemann, Stefan Hägele-Link, Sarah Bolt, Claudia Baum, Gabriela Rettenmund and 11 more

Abstract readConsensus Statement
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Jesus Lopez-AlcaldeInstitute for Complementary and Integrative Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland Jesus.Lopez@usz.ch.ORCID http://orcid.org/0000-0002-1598-8790
Anna K TietjenInstitute for Complementary and Integrative Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Yuqian YanInstitute for Complementary and Integrative Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Claudia CanellaInstitute for Complementary and Integrative Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Jürgen BarthInstitute for Complementary and Integrative Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Nina SteinemannEpidemiology, Biostatistics and Prevention Institute. Swiss MS Registry, University of Zurich, Zurich, Switzerland.
Stefan Hägele-LinkHOCH, Kantonsspital St.Gallen Zentrum für Integrative Medizin, St Gallen, Switzerland.
Sarah BoltUniversity Hospital Zurich, Zurich, Switzerland.
Claudia BaumRehabilitation Hospital Zihlschlacht, Zihlschlacht, Thurgau, Switzerland.
Gabriela RettenmundPatient Contributor, St. Gallen, Switzerland.
Viktor von WylEpidemiology, Biostatistics and Prevention Institute. Swiss MS Registry, University of Zurich, Zurich, Switzerland.
Francesco NoninoCochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Review Group, IRCCS Istituto Delle Scienze Neurologiche di Bologna, Bologna, Italy.
L Susan WielandInstitute for Complementary and Integrative Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0003-2157-0603
Xiaying WangDepartment of Information Technology and Electrical Engineering, ETH Zurich, Zurich, Switzerland.
Anton SchmickDepartment of Neurology, University Hospital Zurich, Zurich, Switzerland.
Francesco PagniniDepartment of Psychology, Università Cattolica del Sacro Cuore, Milano, Italy.ORCID http://orcid.org/0000-0003-1612-4211
Jürg KesselringHead of Department Emeritus Neurology and Neurorehabilitation, Kliniken Valens, Valens, Switzerland.
Hosna KhazaeiDepartment of Pharmacology and Toxicology, Alborz University of Medical Sciences, Karaj, Iran (the Islamic Republic of).ORCID http://orcid.org/0009-0000-2294-9776
Iván Pérez-NeriEvidence Synthesis Unit, National Institute of Rehabilitation Luis Guillermo Ibarra Ibarra, Ciudad de Mexico, Mexico.
Ute Studer-MerklePatient Contributor, Luzern, Switzerland.
Claudia M WittInstitute for Complementary and Integrative Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-5440-7805

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis study aimed to develop a core outcome set (COS) for trials evaluating the effects of complementary therapies in people with multiple sclerosis (pwMS). We sought to identify the outcomes most relevant to pwMS, their relatives and friends, healthcare professionals and researchers and to propose these for inclusion in future trials.

designA participatory international research project using a mixed-method approach with qualitative and quantitative methods. The study included a scoping review and a national survey in Switzerland to identify candidate outcomes, followed by an international COS survey to rate the importance of these outcomes. The final phases involved two consensus meetings to refine and finalise the COS.

settingData were sourced from the published literature and input from international stakeholders.

participantspwMS and other relevant stakeholders, including their relatives and friends, healthcare professionals and researchers.

resultsA total of 770 individuals participated in the international COS survey of 39 candidate outcomes (662 pwMS, 27 relatives/friends, 58 healthcare professionals and 23 researchers). According to the survey results, 13 outcomes were added to the COS, 5 were excluded and 21 were classified as 'no consensus'. 13 individuals (six pwMS, one pwMS's friend, three healthcare professionals and three researchers) attended the first consensus meeting. Following the voting on the outcomes without consensus, seven outcomes were added to the COS, four were excluded and 10 outcomes were still classified as 'no consensus'. The six members of the stakeholders advisory board (one pwMS, four healthcare professionals and two researchers) attended the second consensus meeting to define the final COS. Nine additional outcomes were included in the COS. Sexual problems, an outcome previously excluded, were also added. In total, 30 outcomes were included in the final COS.

conclusionWe have developed the first COS for future trials of complementary therapies for pwMS. The use of this COS will promote that future research in complementary therapies is relevant for pwMS and other stakeholders involved in MS care. Future COS research should integrate diverse geographical regions, where perspectives and access to complementary therapies may vary. STUDY REGISTRATION NUMBER: https://osf.io/ys7xt/.

Indexed as

Complementary TherapiesMultiple SclerosisOutcome Assessment, Health CareFemaleHumansMaleSurveys and QuestionnairesSwitzerlandCOMPLEMENTARY MEDICINEMultiple sclerosisPatient Reported Outcome MeasuresQuality of LifeSurveys and Questionnaires

Identifiers

PMID40713053
PMCPMC12306252

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.